Table 2.

Effect of dapagliflozin compared with placebo on PCA-derived metabolite factors

Factors	Annotation	Nominal P value	FDR corrected P value
1	Medium- and long-chain acylcarnitines and dicarboxyl acylcarnitines	0.74	0.88
2	Short-chain dicarboxyl acylcarnitines	0.04	0.27
3	Branched-chain amino acids and branched-chain ketoacids	0.33	0.66
4	Miscellaneous amino acids	0.09	0.35
5	Medium-chain acylcarnitines	0.01	0.14
6	Long-chain acylcarnitines	0.86	0.92
7	Ketone-related metabolites	0.57	0.76
8	Miscellaneous amino acids	0.56	0.76
9	Long-chain dicarboxyl acylcarnitines	0.52	0.76
10	Medium-chain acylcarnitines	0.17	0.46
11	Miscellaneous acylcarnitines	0.92	0.92
12	Aromatic amino acids	0.19	0.46

Model includes randomized treatment group, baseline factor level, age, race/ethnicity, sex, estimated glomerular filtration rate, and type 2 diabetes mellitus.

FDR, false discovery rate; PCA, principal components analysis.